Caris Life Sciences Publishes npj Precision Oncology Study Showing AI -Guided Therapy ...
In the testing cohort, standard molecular risk patients predicted to benefit from FOLFIRINOX achieved substantially longer median overall survival ...
Read the original at prnewswire.com ↗
- Topics
- HealthcareMedia & Creative Work
- Tracked via
- “AI Risks”